Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year ...

A new antifibrotic option for patients living with idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated ...

Liquidia › Biotech Liquidia (NASDAQ: LQDA) had good news to report about its latest commercialized product as the trading ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension ...

Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

Pune: The untimely death of a 25-year-old BHMS student in a Jalna two-wheeler accident on Dec 29, 2025, broke his family's ...

The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...

Estimated YUTREPIA net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in Jun ...

AI and wireless sensing detect five common lung diseases touch-free, enabling early, personalised health monitoring.

In return for the rights to YL201 outside China, MediLink will receive upfront and potential near-term milestone payments ...

A new development in wireless sensing technology that can reliably screen for five common pulmonary diseases could lead to ...

Investing.com -- Insmed Incorporated (NASDAQ:INSM) stock rose 8% Friday morning following the company’s announcement of ...